Complexity in Pharmaceutical Powders for Inhalation: A perspective

Hickey, Anthony

doi:10.14356/kona.2018007

Cited by 15 publications

(8 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are unique physical mechanisms to consider when dispersing dry powders in the micrometer size range including electrostatics, Van der Waals, and capillary forces (Dunber C.A. et al, 1998;Hickey A.J., 2018). However, a solid dosage form offers better chemical stability compared to those in solution.…”

Section: Aerosols For Pulmonary Therapymentioning

confidence: 99%

Consideration of Metal Organic Frameworks for Respiratory Delivery

Stewart

Luz

Mortensen

2021

KONA

View full text Add to dashboard Cite

Metal organic frameworks (MOFs) have garnered increased attention over the past 20 years. Due to their porosity, high surface area, and nearly limitless customization and tunability MOFs have been designed for applications ranging from gas storage and separation to catalysis to sensing to biomedical engineering. Within the latter category, MOFs offer an appealing function for drug delivery as they can be loaded with multiple therapeutic moieties tailored to target specific disorders with triggered and controlled release characteristics. However, there is an unmet need to assess their viability for pulmonary treatment via inhalation. Targeting pulmonary disorders including infectious diseases by delivering medication directly to the lungs attacks the primary site of infection rather than relying on systemic distribution. The inherent advantage of this strategy is maximizing local lung concentrations of the drug. An introduction to inhaled therapies is provided here as a preamble to a brief summary of the current development state of MOF drug delivery systems. This review is intended to highlight the relative disparity between research toward MOFs as pulmonary drug delivery vehicles compared to other delivery platforms. Prospective biomedical applications for inhalable MOFs are also discussed.

show abstract

Section: Aerosols For Pulmonary Therapymentioning

confidence: 99%

Consideration of Metal Organic Frameworks for Respiratory Delivery

Stewart

Luz

Mortensen

2021

KONA

View full text Add to dashboard Cite

show abstract

“…Supercritical fluid technology is another bottom-up technology that generates uniformly sized particles for pulmonary delivery (Sacchetti and Van Oort, 2007). For reviews on dry powder formulation for pulmonary delivery, the readers are directed to articles that broadly cover these topics (Yang, Chan and Chan, 2014;Carvalho et al, 2015;Hickey, 2018).…”

Section: Formulation Innovationsmentioning

confidence: 99%

Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing

Price

Kunda

Muttil

2019

KONA

View full text Add to dashboard Cite

Significant progress has been made over the last half-century in delivering therapeutics by the pulmonary route. Inhaled therapeutics are administered to humans using metered-dose inhalers, nebulizers, or dry powder inhalers, and each device requires a different formulation strategy for the therapeutic to be successfully delivered into the lung. In recent years, there has been a shift to the use of dry powder inhalers due to advantages in the consistency of the dose delivered, ease of administration, and formulation stability. Numerous preclinical studies, involving small and large animals, have evaluated dry powder drugs, vaccines, and immunotherapeutics delivered by the pulmonary route. These studies used different dry powder delivery devices including nose-only, whole-body, and intratracheal administration systems, each of which works with different aerosolization mechanisms. Unfortunately, these delivery platforms usually lead to variable powder deposition in the respiratory tract of animals. In this review, we will discuss obstacles and variables that affect successful pulmonary delivery and uniform powder deposition in the respiratory tract, such as the type of delivery device, dry powder formulation, and the animal model used. We will conclude by outlining factors that enhance the reproducible deposition of dry powders in the respiratory tract of preclinical animal models and identifying knowledge and technology gaps within the field. We will also outline the important factors necessary for successful translation of studies performed in preclinical models to humans.

show abstract

“…As principais vantagens desses dispositivos são a maior estabilidade dos fármacos, pelo fato de serem administrados sob a forma de pó seco, a dispensa de uso de propelentes em sua formulação, a possibilidade de veiculação de uma alta variedade de medicamentos inclusive para terapias sistêmicas com peptídeos e proteínas, além de conter uma ampla faixa de doses (menos que 10 µg até mais que 20 mg). Uma desvantagem dos pós inalatórios orais é a sensibilidade à umidade que, quando presente, pode resultar em aglomeração do pó (MALCOLMSON, 1998;SMITH, 2003;TELKO;HICKEY, 2005;ANSEL, 2007;ISLAM, 2008;HICKEY, 2017 Os dispositivos para pós inalatórios orais são classificados da seguinte maneira:…”

Section: Pó Inalatório Oralunclassified

“…A dose recebida pelo paciente depende de cinco fatores principais como propriedades da formulação (propriedades reológicas, interações fármaco-carreador); tamanho, densidade e morfologia das partículas; desempenho do dispositivo inalatório; correta técnica de inalação e fluxo inspiratório. No caso dos pós inalatórios orais, o paciente deve apresentar um fluxo de ar mínimo inspiratório de 30 mL/min para receber uma dose efetiva(MALCOLMSON, 1998; TELKO e HICKEY, 2005;ISLAM, 2008;HICKEY, 2017). a fluidez das partículas de fármaco e, consequentemente, faz com que as doses liberadas sejam mais precisas, quando comparado ao fármaco sozinho.…”

unclassified